{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:56:01Z","timestamp":1790636161920,"version":"4.1.0"},"reference-count":0,"publisher":"Association of Basic Medical Sciences of FBIH","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomol Biomed"],"abstract":"<jats:p>Fibronectin type III domain-containing protein 4 (FNDC4) is a circulating hepatokine with anti-inflammatory and cardioprotective properties, but its prognostic relevance after ST-segment elevation myocardial infarction (STEMI) remains uncertain. We investigated whether admission serum FNDC4 levels were associated with 12-month major adverse cardiovascular events (MACE) in patients with STEMI undergoing primary or urgent percutaneous coronary intervention (PCI). This single-center prospective observational study included 274 patients. Serum FNDC4 was measured before PCI using an enzyme-linked immunosorbent assay, and participants were followed for 12 months. Associations and prognostic performance were assessed using Spearman correlation, receiver operating characteristic, Kaplan\u2013Meier, and Cox proportional hazards analyses. During follow-up, 51 patients (18.6%) experienced MACE. Serum FNDC4 levels were significantly lower in patients with MACE and were inversely correlated with interleukin-6 (IL-6) and N-terminal pro\u2013B-type natriuretic peptide (NT-proBNP). The area under the receiver operating characteristic curve (AUC) for FNDC4 was 0.771 (95% confidence interval [CI], 0.695\u20130.839). Adding FNDC4 to a clinical model increased the AUC from 0.874 to 0.905 (\u0394AUC, 0.031; 95% CI, 0.009\u20130.061). After adjustment for age, NT-proBNP, left ventricular ejection fraction (LVEF), estimated glomerular filtration rate (eGFR), and Killip class III\/IV, each 10 ng\/mL decrease in FNDC4 was associated with a higher risk of MACE (hazard ratio, 1.821; 95% CI, 1.360\u20132.438; p&lt;0.001). Lower admission FNDC4 levels were independently associated with 12-month MACE after PCI for STEMI and may provide complementary prognostic information; however, multicenter external validation and serial FNDC4 measurements are required before clinical application.<\/jats:p>","DOI":"10.17305\/bb.2026.14625","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:03:24Z","timestamp":1788872604000},"source":"Crossref","is-referenced-by-count":0,"title":["Circulating FNDC4 levels and 12-month major adverse cardiovascular events in patients with STEMI undergoing PCI: A prospective cohort study"],"prefix":"10.17305","author":[{"given":"Xiaojun","family":"Pu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengchao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6922","published-online":{"date-parts":[[2026,9,8]]},"container-title":["Biomolecules and Biomedicine"],"original-title":[],"link":[{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/14625\/4319","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/14625\/4319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:00:43Z","timestamp":1790632843000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/view\/14625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":0,"URL":"https:\/\/doi.org\/10.17305\/bb.2026.14625","relation":{},"ISSN":["2831-090X","2831-0896"],"issn-type":[{"value":"2831-090X","type":"electronic"},{"value":"2831-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,8]]}}}